Banco de dados - (CIANE)

Descrição deste banco de dados documental (Site da CIANE)
Atualmente 3111 fichas
➡ Canal do YouTube (tutorial)

https://ciane.net/id=2751

Criado em : 26 Nov 2017
Alterado em : 26 Nov 2017

➡ Modificar esta ficha
Siga este link somente se você tiver um palavra chave de editor!

Nota bibliográfica (sem autor) :

Labor induction for premature rupture of membranes using vaginal misoprostol versus dinoprostone vaginal insert - American Journal of Perinatology - Vol. 31, 3 - p.181-185

Autores :

Abraham, C.; Meirowitz, N.; Kohn, N.

Ano de publicação :

2014

URL(s) :

https://www.scopus.com/inward/record.uri?eid=2-s2.…
https://doi.org/10.1055/s-0033-1343768

Résumé (français)  :

Abstract (English)  :

Objective: To compare labor induction outcomes using vaginal misoprostol versus dinoprostone insert in women with premature rupture of membranes (PROM) and an unfavorable cervix. Study Design: Charts of singleton gestations beyond 34 weeks with PROM and an unfavorable cervix from 2008 to 2011 were reviewed. Group assignment was determined by initial induction agent used. Dinoprostone was administered as a 10-mg vaginal insert left for up to 12 hours. Misoprostol was administered vaginally as a 25-μg tablet every 4 hours for up to six doses. Times to active labor, complete dilatation, and delivery and incidence of adverse outcomes (intrapartum fever, tachysystole, fetal heart rate abnormalities) were compared. Results: Ninety-eight women were included. Baseline characteristics between groups were not different. Median times to active labor (7 versus 11 hours, p < 0.001) and complete dilatation (13.5 versus 19 hours, p < 0.001) were shorter in the misoprostol group. In the misoprostol group, 41.7 and 88.4% of patients delivered vaginally within 12 and 24 hours, respectively, compared with 20.8 and 58.0% in the dinoprostone group (p < 0.001). There was no difference in incidence of adverse outcomes. Conclusion: Vaginal misoprostol is more effective than dinoprostone insert for induction secondary to PROM without increasing the incidence of adverse outcomes. Copyright © 2014 by Thieme Medical Publishers, Inc.

Sumário (português)  :

Resumen (español)  :

Comentários :

Argument (français) :

Argument (English):

Argumento (português):

Argumento (español):

Palavras-chaves :

➡ indução ; misoprostol (Cytotec)

Autor da esta ficha :

Import 26/11/2017 — 26 Nov 2017